Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

250.61

+1.79 (0.72%)

as of Jul 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.

Consensus

Buy

Valuation

Fair Value

Similar

DON'T BUY

Health care is not one of the sectors to perform well in the economic recovery. Big company, but the charts are below the 200 and 50 day moving average. Not tremendous growth. Doesn’t see a compelling valuation.

PAST TOP PICK

(A Top Pick Nov 3/10. Down 5.1%.) Still Buying.

PAST TOP PICK

(A Top Pick Jan 5/10. Down 1.33%.)

BUY

Been an iconic company and has done very well but stumbled lately with a series of recalls including Benadrol, Tylenol and Motren, which has hurt them on the consumer side. Last earnings report saw shrinkage of about 11% on the consumers’ side. Probably an opportunity for the longer term. Good balance sheet.

PAST TOP PICK

(Top Pick Jan 26/09, Up 4.39%)

BUY

Has a model price of $75.13, a positive differential of 19%. Fundamentally looks good to him. Historically you could never Buy it below its model price but now you have the opportunity.

BUY ON WEAKNESS

Has run up in the last little while but feels you can get it at a lower level. Very defensive.

BUY

Suffering a little on their consumer product lines. Good value longer term. Will probably earn $5.25-$5.35 this year and are trading at about 11X. Solid dividend.

TOP PICK

Large cap quality name that is reasonably valued. 3.3% dividend, 13.5x earnings. Not a lot of downside. Not enormous upside. Dividend is almost 1% above 10-year treasury.

BUY

Very large consumer products and medical products company. 2.7% yield. Debt is 35% less than assets. Big international exposure.

BUY

Baxter and Abbot Labs are similar. He feels health care is a place to invest now.

TOP PICK

AAA balance sheet. Excellent dividend at about 3.5%. A lot of cash but recently acquired some debt at very attractive rates.

BUY

Great company. Pharmaceutical, medical devices and consumer products, which he likes. Has acted defensively. Great yield and great balance sheet.

BUY

3 distinct divisions. Pharmaceuticals, consumer products and medical devices. This translates them from the fluctuations from patent risks. Be cautious when looking at the Pharma sector that you don't look at trailing earnings and yield because forward earnings can look quite different when drugs come off patent.

BUY

Had some missteps in terms of quality control on Tylenol and on some of their medical device operation. Well priced and good opportunity to get in. Good management. Good dividend and great balance sheet and well diversified between pharmaceuticals, medical devices and consumer business.

Showing 436 to 450 of 628 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Julien Nono-Womdim

Goodreid Investment Council

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)